A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas
A Phase 2 Study to Assess the Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy.
Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms.
Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment.
Arm 2 participants will receive daily hedgehog pathway inhibitor, and 1 cycle of SP-002 treatment.
Arm 3 participants will receive daily hedgehog pathway inhibitor only.
100 项与 Stamford Pharmaceuticals, Inc. 相关的临床结果
0 项与 Stamford Pharmaceuticals, Inc. 相关的专利(医药)
100 项与 Stamford Pharmaceuticals, Inc. 相关的药物交易
100 项与 Stamford Pharmaceuticals, Inc. 相关的转化医学